Nature

ITK signalling via the Ras/IRF4 pathway regulates the development and function of Tr1 cells

T regulatory (Treg) cells promote immune tolerance and suppress inflammation 1,2. Unlike Treg cells that stably express the transcription factor Foxp3, type 1 regulatory T (Tr1) cells have no or ...
Nasdaq

Aclaris Therapeutics Announces Positive Results from Phase 1 Multiple Ascending Dose Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor

that ATI-2138 was generally well tolerated at all doses tested in the trial; that ATI-2138 had dose proportional pharmacokinetics (PK); and a dose-dependent inhibition of both ITK and JAK3 exploratory ...
Yahoo Finance

Corvus Pharmaceuticals Presents Soquelitinib Preclinical Data Highlighting Potential of ITK inhibition to Treat Systemic Sclerosis at EULAR 2025 Congress

SOUTH SAN FRANCISCO, Calif., June 11, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clinical-stage biopharmaceutical company, today announced preclinical data highlighting ...
Yahoo Finance

Aclaris Therapeutics Announces First Patient Dosed in Phase 2a Clinical Trial of ATI-2138, an Investigational Oral Covalent ITK/JAK3 Inhibitor for the Treatment of Moderate to ...

WAYNE, Pa., Sept. 17, 2024 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel drug candidates for immuno-inflammatory ...
Seeking Alpha

Corvus Pharmaceuticals: Ahead Of The Clinical-Stage Curve

Corvus Pharmaceuticals is a clinical-stage company with potential investment opportunities and a focus on the ITK inhibitor soquelitinib. The company is targeting relapsed peripheral T-cell lymphoma ...